Researchers Link Brain Growth Deficits to Gene Protein

A study at Washington University in St. Louis identified a protein link to neurological impairment in Angelman syndrome.

Updated on Oct. 21, 2026 in Autism

Researchers Link Brain Growth Deficits to Gene Protein

Live Poll

Do you believe new research on rare genetic diseases will lead to successful human treatments?

Researchers have discovered that elevated levels of asparagine synthetase in neurons contribute to impaired brain growth in Angelman syndrome. By blocking this protein in mice, scientists were able to restore normal brain development.

Why it matters

This finding marks the first time increased asparagine synthetase has been linked to a specific neurological condition. Understanding this mechanism offers a potential pathway for medical interventions to address the developmental challenges faced by children with the syndrome.

Angelman syndrome occurs in roughly one in 20,000 births, and researchers identified 23 proteins that increase when the UBE3A gene is deactivated. This study represents the first evidence linking asparagine synthetase levels to neurological conditions.

The players

Washington University School of Medicine

This St. Louis-based medical research institution is a leading academic center for medical education and scientific discovery.

The details

The absence of the UBE3A gene triggers a stress response in brain neurons that causes them to conserve resources and curb protein production. By neutralizing asparagine synthetase, researchers successfully reversed the growth deficits observed in the test models.

Cognitive and mobility deficits in affected individuals typically become evident by 6 months of age.
The study findings were officially published in Nature on October 21, 2026.

The Big Picture

This research clarifies the specific downstream biological mechanism triggered by the UBE3A gene deletion associated with Angelman syndrome. It moves the field beyond simply identifying the missing gene toward understanding how that absence ripples through cellular pathways.

While this study provides a new target for potential therapies, it does not currently change immediate clinical treatment plans for children with the syndrome. Families can expect continued research into the timing of future interventions to address developmental delays.

The takeaway

This discovery highlights how cellular stress responses can directly influence brain size and development. It provides a foundational model for researchers to test future therapies aimed at restoring normal neurological function in those affected.